KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $627.7 million.

  • Regeneron Pharmaceuticals' Current Deferred Revenue fell 13.01% to $545.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.6 million, marking a year-over-year decrease of 13.01%. This contributed to the annual value of $627.7 million for FY2024, which is 36.78% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Current Deferred Revenue of $627.7 million as of FY2024, which was up 36.78% from $458.9 million recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Current Deferred Revenue peaked at $627.7 million during FY2024, and registered a low of $442.0 million during FY2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $477.9 million (2022), whereas its average is $521.5 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 46.07% in 2020, then decreased by 23.49% in 2021.
  • Regeneron Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $577.7 million in 2020, then fell by 23.49% to $442.0 million in 2021, then grew by 8.12% to $477.9 million in 2022, then dropped by 3.98% to $458.9 million in 2023, then skyrocketed by 36.78% to $627.7 million in 2024.